Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the transaction, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Adam Laponis also recently made the following trade(s):
- On Friday, April 17th, Adam Laponis sold 4,000 shares of Twist Bioscience stock. The shares were sold at an average price of $60.00, for a total transaction of $240,000.00.
- On Tuesday, April 14th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $55.00, for a total transaction of $165,000.00.
Twist Bioscience Price Performance
Shares of TWST opened at $90.35 on Tuesday. The business’s 50-day moving average is $74.97 and its two-hundred day moving average is $56.51. The company has a market capitalization of $5.63 billion, a P/E ratio of -67.93 and a beta of 2.11. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $105.47.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the company. UBS Group set a $89.00 price target on Twist Bioscience in a research note on Monday, June 15th. Canaccord Genuity Group began coverage on Twist Bioscience in a report on Monday, June 15th. They issued a “buy” rating and a $90.00 price objective on the stock. Piper Sandler began coverage on Twist Bioscience in a research report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price objective for the company. Guggenheim upped their target price on Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.30.
Get Our Latest Stock Analysis on TWST
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. William Blair Investment Management LLC boosted its holdings in Twist Bioscience by 43.7% in the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after buying an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. increased its stake in Twist Bioscience by 71.1% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock worth $114,876,000 after buying an additional 1,696,377 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Twist Bioscience by 151.5% during the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after acquiring an additional 1,080,722 shares during the last quarter. ARK Investment Management LLC raised its holdings in shares of Twist Bioscience by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after acquiring an additional 832,687 shares during the last quarter. Finally, Balyasny Asset Management L.P. lifted its position in shares of Twist Bioscience by 934.0% in the second quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock valued at $23,113,000 after acquiring an additional 567,481 shares in the last quarter.
About Twist Bioscience
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
- Five stocks we like better than Twist Bioscience
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
